Kidney drug, Zerenex
reporting positive late-stage data on its kidney disease drug, Zerenex.
Cancer drug trial:
Wednesday, 31 Aug 2011 11:27am EDT
Reuters reported that Keryx Biopharmaceuticals said that an independent safety panel has given its go-ahead for a late-stage trial of its experimental drug for colorectal cancer. The independent Data Safety Monitoring Board completed an interim analysis for safety and futility on the drug and recommended the late-stage study continue to completion. The late stage trial is being studied to treat colorectal cancer in more than 465 randomized patients with refractory advanced colorectal cancer.
Keryx Biopharmaceuticals, Inc. (Keryx) is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and renal disease. The Company is developing KRX-0401, an oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, and also affects a number of other key signal transduction pathways, including the Jun N-terminal kinases pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and survival. KRX-0401 is in Phase III clinical development for both refractory advanced colorectal cancer and relapsed / refractory multiple myeloma, and in Phase I and Phase II clinical development for other tumor types. It is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes.
No comments:
Post a Comment